Veracyte, Inc. announced it has met its targeted enrollment for the NIGHTINGALE trial, which aims to evaluate the clinical utility of its Percepta Nasal Swab test.
The milestone marks an important step in Veracyte’s goal of making the novel molecular test widely available and helping clinicians to better guide next steps for patients with potentially cancerous lung nodules.
The prospective, randomized, blinded NIGHTINGALE trial has now successfully enrolled 2,400 patients at over 90 academic and community centers across the United States. Patients have been randomized to those whose Percepta Nasal Swab test result was provided to their physician, and the control group. Patients will be followed for up to two years to assess the molecular test’s ability to reduce unnecessary procedures in those with low-risk, benign nodules and to assess whether the test helps accelerate treatment for those with cancerous nodules.
The Percepta Nasal Swab test uses a simple brush to acquire nasal epithelial cells for the assessment of molecular changes linked to lung cancer risk in patients with lung nodules and a history of smoking. The test was developed using whole-transcriptome sequencing and machine learning.
